C4 Therapeutics, Inc. (CCCC) Operating income 2019–2025
C4 Therapeutics, Inc. (CCCC) annual operating income history from SEC filings — each fiscal year as reported.
-$115.2MFY2025 · since FY2019: -$35.5M → -$115.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$115.2M | +3.7% |
| FY2024 | -$119.6M | +14.0% |
| FY2023 | -$139.0M | -7.3% |
| FY2022 | -$129.5M | -57.7% |
| FY2021 | -$82.1M | -35.9% |
| FY2020 | -$60.4M | -70.5% |
| FY2019 | -$35.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CCCC financial trends
CCCC RevenueCCCC Net incomeCCCC Net marginCCCC Gross profitCCCC Gross marginCCCC Operating marginCCCC Operating cash flowCCCC Free cash flowCCCC Capital expendituresCCCC Return on equityCCCC Stock buybacksCCCC Dividends paidCCCC Total assetsCCCC Total liabilitiesCCCC Shareholders’ equityCCCC overview →